|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 USD | -10.31% |
|
-8.68% | -68.20% |
| 05-24 | Roche, LumiraDx Deal Probed by U.K. Competition Watchdog | DJ |
| 05-20 | U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx | DJ |
LumiraDx Limited reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was USD 41.12 million compared to USD 118.25 million a year ago. Net loss was USD 102.19 million compared to USD 37.06 million a year ago.
Basic loss per share from continuing operations was USD 0.32 compared to USD 0.15 a year ago. Diluted loss per share from continuing operations was USD 0.32 compared to USD 0.15 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -68.20% | 7.18M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
LUMIRADX LIMITED 
